[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Park JS, Kim L, Kim CH, Bang BW, Lee DH, Jeong S, Shin YW, Kim HG: Synchronous large-cell neuroendocrine carcinoma and adenocarcinoma of the colon. Gut Liver; 2010 Mar;4(1):122-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous large-cell neuroendocrine carcinoma and adenocarcinoma of the colon.
  • Large-cell neuroendocrine carcinoma of the colon is a rare entity with a prognosis that is usually poor due to the high likelihood of early metastasis.
  • A 61-year-old man had surgery for colon cancer of the transverse colon and cecum.
  • Microscopic examination of the tumor showed that the location was the proximal transverse colon, with small nests containing rosettes and palisading patterns of large tumor cells with faintly granular cytoplasm.
  • The tumors were diagnosed as a large-cell neuroendocrine carcinoma of the colon.
  • In addition, the tumor of the cecum showed microscopic findings consistent with a well-differentiated adenocarcinoma.
  • Postoperative chemotherapy was applied.
  • This is the first case of a synchronous large-cell neuroendocrine carcinoma and adenocarcinoma of the colon.
  • The patient was treated successfully with debulking surgery and systemic chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Esp Enferm Dig. 2008 Jan;100(1):11-6 [18358055.001]
  • [Cites] Int J Colorectal Dis. 2008 Mar;23(3):325-7 [18064472.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):553-76 [16183527.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):491-505 [16183523.001]
  • [Cites] Pathol Int. 2005 Aug;55(8):524-9 [15998383.001]
  • [Cites] Gynecol Oncol. 2001 Jul;82(1):187-91 [11426984.001]
  • [Cites] Surgery. 1994 Jun;115(6):762-6 [8197570.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:13-27 [15153416.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1049-51 [15154621.001]
  • [Cites] Virchows Arch. 2002 Sep;441(3):256-63 [12242522.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3500-5 [8012973.001]
  • (PMID = 20479925.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2871610
  • [Keywords] NOTNLM ; Chemotherapy / Colonic neoplasms / Multiple primary neoplasms / Neuroendocrine carcinoma
  •  go-up   go-down


2. Carneiro BA, Kaminer L, Eldibany M, Sreekantaiah C, Kaul K, Locker GY: Oxaliplatin-related acute myelogenous leukemia. Oncologist; 2006 Mar;11(3):261-2
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 56-year-old woman diagnosed with a poorly differentiated cecal adenocarcinoma with metastases to ovaries, omentum, and sigmoid colon went into remission after 12 cycles of infusional 5-fluorouracil, luecovorin, and oxaliplatin (FOLFOX-4 regimen).
  • Bone marrow biopsy was consistent with therapy-related acute myelogenous leukemia.
  • Chromosome analysis showed structural rearrangements with partial deletions of the long arms of chromosomes 5, 7, 20, and 21, as well as trisomy of chromosome 8 and losses of chromosomes 3 and 11.
  • Induction chemotherapy led to remission, but the patient died two months later from complications of colon cancer progression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid, Acute / chemically induced
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Cecal Neoplasms / drug therapy. Cecal Neoplasms / pathology. Chromosome Deletion. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Middle Aged. Omentum / pathology. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / secondary. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / secondary. Trisomy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16549810.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 2S9ZZM9Q9V / Bevacizumab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


3. Chintamani, Singhal V, Bansal A, Bhatnagar D, Saxena S: Isolated colostomy site recurrence in rectal cancer-two cases with review of literature. World J Surg Oncol; 2007;5:52
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both patients had received adjuvant chemotherapy following surgery.
  • CASE PRESENTATION: First case was a 30-year-old male that had reported with large bowel obstruction due to an obstructing ulcero-proliferative growth (poorly differentiated adenocarcinoma) at the colostomy site after abdomino-perineal resection, performed for low rectal cancer six years previously.
  • Second case was a 47-year-old male that presented with acute large bowel obstruction due to an annular growth (well differentiated adenocarcinoma) in the upper rectum.
  • Five years following closure of colostomy, he presented with two parietal masses at the previous colostomy site scar, which, on fine needle aspiration cytology were found to be well-differentiated adenocarcinomas of colorectal type.
  • [MeSH-major] Adenocarcinoma / pathology. Colostomy / adverse effects. Neoplasms, Second Primary / pathology. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2002;37(5):387-90 [12051539.001]
  • [Cites] J Postgrad Med. 2003 Apr-Jun;49(2):157-8 [12867694.001]
  • [Cites] Gastroenterology. 1958 Jan;34(1):85-98 [13501357.001]
  • [Cites] Cancer. 1974 Jun;33(6):1630-4 [4834157.001]
  • [Cites] Dis Colon Rectum. 1983 Jan;26(1):50-2 [6822162.001]
  • [Cites] Dis Colon Rectum. 1966 Nov-Dec;9(6):441-6 [5926156.001]
  • (PMID = 17567928.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 10
  • [Other-IDs] NLM/ PMC1876234
  • [General-notes] NLM/ Original DateCompleted: 20070730
  •  go-up   go-down


Advertisement
4. Mondal SK: Primary squamous cell carcinoma of the cecum. J Cancer Res Ther; 2009 Oct-Dec;5(4):328-30
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, a well-differentiated, keratinizing SSC of cecum in a 34-year-old male patient is being reported.
  • Clinical features were that of an adenocarcinoma of the colon.
  • Postoperative chemotherapy was given for 6 months to eradicate any micrometastasis.
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20160376.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


5. Pilati P, Mocellin S, Rossi CR, Foletto M, Campana L, Nitti D, Lise M: Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. Ann Surg Oncol; 2003 Jun;10(5):508-13
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma.
  • BACKGROUND: Hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) has been recently proposed to treat peritoneal carcinomatosis arising from colon adenocarcinoma, which is usually regarded as a lethal clinical entity.
  • The purpose of this study was to evaluate the clinical outcome of this combined treatment.
  • METHODS: A retrospective study of 46 patients treated for peritoneal carcinomatosis from colon adenocarcinoma was performed.
  • The 2-year overall survival was 31%, and the median survival time and the median time to local disease progression were 18 and 13 months, respectively.
  • Survival and local disease control in patients with well- and moderately differentiated colon adenocarcinoma were significantly better than in those with poorly differentiated tumors.
  • CONCLUSIONS: Considering the dismal prognosis of this condition, HIIC seems to achieve encouraging results in a selected group of patients affected with resectable peritoneal carcinomatosis arising from colon adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / secondary. Colonic Neoplasms / pathology. Hyperthermia, Induced. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Cell Differentiation. Cisplatin / administration & dosage. Combined Modality Therapy. Disease Progression. Female. Humans. Infusions, Parenteral. Male. Middle Aged. Mitomycin / administration & dosage. Prognosis. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2003 Jun;10(5):484-5 [12794010.001]
  • (PMID = 12794016.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Kaneki T, Koizumi T, Kawashima A, Tsushima K, Kubo K, Fujimoto K, Honda T, Akamatsu T: Double cancer (lung and colon cancer) that showed complete remission with irinotecan and cisplatin combined chemotherapy. J Gastroenterol; 2000;35(11):864-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double cancer (lung and colon cancer) that showed complete remission with irinotecan and cisplatin combined chemotherapy.
  • We report a rare case of double (colon and lung) cancer which showed complete remission with chemotherapy with irinotecan (CPT-11) and cisplatin (CDDP).
  • The patient was a 67-year-old man who was diagnosed as having double cancer (stage IIIb pulmonary adenocarcinoma and stage 0 [or 1] well-differentiated adenocarcinoma of the ascending colon).
  • Two courses of chemotherapy (CPT-11, 60 mg/m2, days 1 and 8; CDDP, 30 mg/m2, days 1 and 8) were performed.
  • The combination therapy of CPT-11 and CDDP was very effective.
  • In Japan, there have been few published reports describing the use of CPT-11 for the treatment of gastrointestinal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Colonic Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Neoplasms, Multiple Primary / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11085497.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Futamura N, Matsutomo M, Yasumura M, Tateyama K, Sakamoto K: [A case of multiple liver metastases from colon cancer successfully treated with pharmacokinetic modulating chemotherapy]. Gan To Kagaku Ryoho; 2003 Sep;30(9):1357-60
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of multiple liver metastases from colon cancer successfully treated with pharmacokinetic modulating chemotherapy].
  • After examination to identify the cause of anemia, she was diagnosed with sigmoid colon cancer and multiple liver metastasis.
  • Histopathological examination of the resection specimen revealed well-differentiated adenocarcinoma, with a depth of tumor invasion of ss and positive lymph node metastasis.
  • Pharmacokinetic modulating chemotherapy (PMC) was performed after the operation.
  • PMC was continued, but the hepatic artery became occluded 1 year and 11 months after the operation, and so PMC was replaced by systemic chemotherapy of 5-FU plus levofolinate at 2 years after the operation.
  • This chemotherapy was discontinued after 3 courses.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / pathology. Infusion Pumps, Implantable. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Chemotherapy, Adjuvant. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Infusions, Intra-Arterial. Infusions, Intravenous. Middle Aged. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14518421.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; U3P01618RT / Fluorouracil; 1-UFT protocol
  •  go-up   go-down


8. Ishikawa T, Nakamura M, Ohkuma K, Hisano C, Nakano S, Maruyama T, Kaji Y, Niho Y, Masumoto N: [A case of metastatic colon carcinoma in which a continuous intrahepatic artery-infusion of 5-FU leucovorin and cisplatin, and systemic chemotherapy with CPT-11 was very effective]. Gan To Kagaku Ryoho; 2000 Aug;27(9):1443-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metastatic colon carcinoma in which a continuous intrahepatic artery-infusion of 5-FU leucovorin and cisplatin, and systemic chemotherapy with CPT-11 was very effective].
  • We report a patient with metastatic colon carcinoma who was treated effectively with a continuous intrahepatic artery-infusion of 5-FU, Leucovorin and cisplatin, and systemic chemotherapy with CPT-11.
  • A 50-year-old man was diagnosed as having well differentiated adenocarcinoma of the sigmoid colon with multiple liver metastases in March, 1997.
  • He was treated with 3 courses of continuous intrahepatic artery-infusion of 5-FU, Leucovorin and cisplatin, and two courses of systemic chemotherapy with CPT-11 during hospitalization, followed by 6 courses of a similar intraarterial therapy in an outpatient setting.
  • During the 6th course of intraarterial therapy, diarrhea, nausea, and vomiting appeared and angiography revealed a narrowing of the hepatic artery.
  • Therefore, the intrahepatic artery-infusion therapy was reinitiated with doses of 5-FU, Leucovorin and cisplatin reduced to approximately 80%.
  • After 5 courses of this therapy, the computed tomography scan showed a marked decrease in the size of the metastatic hepatic lesions by 90%, and the serum level of CEA decreased from 657.7 ng/ml to 4.5 ng/ml.
  • No severe side effects were seen during the treatment.
  • Though multiple lung metastases were indicated during the intrahepatic artery-infusion therapy, both the liver and lung metastases have been well controlled with continuous intrahepatic artery-infusion chemotherapy and systemic chemotherapy.
  • The continuous intrahepatic arterial infusion of 5-FU, leucovorin and cisplatin appears to be very effective for the treatment of colon carcinoma with liver metastasis without reducing the quality of life.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Colonic Neoplasms / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Administration Schedule. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Infusion Pumps, Implantable. Infusions, Intra-Arterial. Leucovorin / administration & dosage. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10969604.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; PFL protocol
  •  go-up   go-down


9. Iitaka D, Ikoma H, Kawaguchi T, Murayama Y, Komatsu S, Shiozaki A, Kuriu Y, Nakanishi M, Ichikawa D, Fujiwara H, Okamoto K, Ochiai T, Kokuba Y, Sonoyama T, Konishi H, Yoshikawa T, Otsuji E: [A case report--locally advanced pancreatic adenocarcinoma was resected after chemotherapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2358-60
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report--locally advanced pancreatic adenocarcinoma was resected after chemotherapy].
  • We performed a pancreatic tail resection along with combined resection of third and fourth portions of the duodenum, transverse colon and splenic flexure, and left adrenal gland.
  • The case was diagnosed to be well-differentiated invasive ductal pancreatic cancer with duodenal invasion.
  • In this case, the treatment was initially started by considering the case as one of duodenal cancer, but the final results of a pathological diagnosis revealed that it was pancreatic cancer.
  • However, either way, even though the case was unresectable before the chemotherapy performed for duodenal cancer was significantly effective for the pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / therapy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Combinations. Duodenal Neoplasms / pathology. Duodenal Neoplasms / therapy. Humans. Male. Mesenteric Artery, Superior / pathology. Neoplasm Invasiveness. Oxonic Acid / administration & dosage. Taxoids / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224572.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Yamamoto A, Ishibashi K, Tajima Y, Hatano S, Ishiguro T, Osawa T, Okada N, Kumamoto K, Yokoyama M, Haga N, Ishida H: [Successfully resected an isolated extraperitoneal metastasis of sigmoid colon cancer--a case report]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2644-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successfully resected an isolated extraperitoneal metastasis of sigmoid colon cancer--a case report].
  • We herein report an extremely rare operative case of an isolated extraperitoneal metastasis of colon cancer.
  • A female patient had undergone a sigmoidectomy for ileus due to sigmoid colon cancer when she was 40 years old.
  • Peritoneal metastasis, 5 mm in diameter, was on the sigmoid colon mesentery and she was histologically diagnosed as Stage IV.
  • She received fluorouracil-based adjuvant chemotherapy for 24 months.
  • Serum CEA increased in spite of giving UFT/LV, so we changed to mFOLFOX6 therapy.
  • Serum CEA decreased until it reached to a normal range after 9 courses, and stopped mFOLFOX6 therapy.
  • A histological examination of the tumor revealed a moderately differentiated adenocarcinoma similar to colon cancer.
  • She has been well without recurrence 77 months after the first operation.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Ovarian Neoplasms / secondary. Pelvic Neoplasms / secondary. Sigmoid Neoplasms / pathology. Sigmoid Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224666.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


11. mukai M, Moriya H, Himeno S, Oida Y, mukohyama S, Nishi T, Nakasaki H, Satoh S, Makuuchi H: Efficacy of oral UFT plus leucovorin therapy for colon cancer with ovarian and multiple liver metastases: report of two cases. Oncol Rep; 2001 Sep-Oct;8(5):1079-83
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of oral UFT plus leucovorin therapy for colon cancer with ovarian and multiple liver metastases: report of two cases.
  • Case 1: a patient was diagnosed as having ascending colon cancer with right ovarian metastasis, and underwent palliative right hemicolectomy plus oophorectomy.
  • The tumor was a well-differentiated adenocarcinoma with right ovarian metastasis, and the disease was classified as stage IV.
  • Oral chemotherapy with UFT plus LV was performed for about 3 years, and the patient is still being followed up with no recurrence at 5 years postoperatively.
  • Case 2: a patient was diagnosed as having incomplete large bowel obstruction caused by ascending colon cancer, and underwent curative right hemicolectomy.
  • The tumor was a moderately differentiated adenocarcinoma, and the disease was classified as stage II.
  • Since multiple liver metastases developed at 3 months postoperatively, oral chemotherapy with UFT plus LV was started.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Leucovorin / therapeutic use. Liver Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Tegafur / therapeutic use. Uracil / therapeutic use
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Colectomy. Female. Humans. Neoplasm Staging. Ovariectomy. Postoperative Period. Remission Induction. Tomography, X-Ray Computed


12. Aranda E, Abad A, Carrato A, Cervantes A, Tabernero J, Díaz-Rubio E, TTD Group: Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy). Clin Transl Oncol; 2006 Feb;8(2):98-102
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy).
  • The choice of the most suitable chemotherapy schedule for the adjuvant treatment of colon cancer has been reviewed by the TTD group, as well as the principles of risk assessment for patients with stage II disease.
  • In patients with stage II disease, the indication of chemotherapy must be individualized and based on the patient's risk of recurrence (perforation, obstruction, peritumoral lymphovascular involvement, poorly differentiated histology, number of lymph nodes examined < or = 11, pre-surgical CEA), and comorbidities that can compromise the safety of treatment or survival of the patient.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Algorithms. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Capecitabine. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Lymphatic Metastasis. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Randomized Controlled Trials as Topic. Risk Assessment. Tegafur / administration & dosage. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] Clin Colorectal Cancer. 2005 Mar;4(6):384-9 [15807931.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2936-43 [8523058.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1797-806 [15067028.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2896-903 [12885807.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8664-70 [16260700.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3395-407 [15199087.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Ann Oncol. 2009 Apr;20(4):674-80 [19179549.001]
  • [Cites] Br J Cancer. 2001 Nov 16;85(10):1437-43 [11720425.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 5:v61-118 [14684501.001]
  • (PMID = 16632423.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; 1-UFT protocol; Folfox protocol
  •  go-up   go-down


13. Ui T, Horie H, Sato H, Miyakura Y, Sakuma Y, Hyodo M, Togashi K, Yasuda Y, Nagai H, Matsubara D: [Sigmoid colon cancer in a woman developing 22 years after radiation therapy for a yolk sac tumor]. Nihon Shokakibyo Gakkai Zasshi; 2009 May;106(5):668-73
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sigmoid colon cancer in a woman developing 22 years after radiation therapy for a yolk sac tumor].
  • She had undergone surgical resection following chemotherapy for yolk sac tumor at the age of 12 years, and had received additional surgery and radiation therapy for a local recurrence at age 13.
  • Following evaluation, a sigmoid colon tumor was detected and was surgically resected.
  • Histology proved well differentiated adenocarcinoma with chronic irradiation colitis, suggesting that irradiation may have induced the colon cancer.
  • [MeSH-major] Adenocarcinoma / etiology. Endodermal Sinus Tumor / radiotherapy. Ovarian Neoplasms / radiotherapy. Radiotherapy / adverse effects. Sigmoid Neoplasms / etiology
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Chronic Disease. Colitis / etiology. Female. Humans. Neoplasm Recurrence, Local. Ovariectomy. Time Factors

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19420871.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Trafalis DT, Geromichalos GD, Bountouroglou N, Koumbi D, Kontos M, Sougias D, Dalezis P, Karamanakos P, Papageorgiou A, Camoutsis C, Athanassiou AE: A preclinical survey on the efficacy of lactandrate in the treatment of colon carcinoma. J BUON; 2005 Apr-Jun;10(2):227-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A preclinical survey on the efficacy of lactandrate in the treatment of colon carcinoma.
  • PURPOSE: There has been a recent and dramatic increase in the pace of drug development for colorectal cancer which holds promise to further improve curative therapy.
  • We tested lactandrate, an alkylating ester of D-lactam androsterone, for antineoplastic activity against colon adenocarcinoma in vitro and in vivo.
  • MATERIALS AND METHODS: The cytostatic and cytotoxic activity of lactandrate were evaluated in vitro against 9 human colon adenocarcinoma cell lines.
  • The in vitro testing was performed with the sulforhodamine B (SRB) colorimetric assay and the mean concentrations of each drug that generated 50% (GI50) or total (100%) growth inhibition (TGI), as well as the drug concentrations that produced cytotoxicity against 50% of the cultured cells (IC50) were calculated.
  • The in vivo antitumour effect was determined against two rodent colon carcinomas, the Colon 26 and the relatively chemoresistant Colon 38 carcinoma, as well as against the human xenograft CX-1 colon carcinoma.
  • RESULTS: Lactandrate displayed a satisfactory activity against the 9 human colon cancer cell lines, inducing significant growth inhibition and cytotoxicity.
  • Lactandrate induced antiproliferative activity against colon cancer cell lines linearly correlated with the carcinoembryonic antigen (CEA) production.
  • The more differentiated cell lines DLD-1 and HCC2998 appeared more resistant to the cytostatic effect of lactandrate.
  • In vivo, the compound produced a significant antitumour activity against Colon 26 and Colon 38, as well as a moderate antitumour effect against CX-1 colon carcinoma.
  • CONCLUSION: Preclinical research supports the high in vitro and in vivo antitumour potential of lactandrate against colon carcinoma.
  • Therefore, lactandrate represents an important candidate drug for further clinical development.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343334.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


15. Shnyder SD, Cooper PA, Pettit GR, Lippert JW 3rd, Bibby MC: Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model. Anticancer Res; 2003 Mar-Apr;23(2B):1619-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model.
  • BACKGROUND: The tubulin depolymerizing drug Combretastatin A-1 phosphate (CA1P), a water-soluble derivative of combretastatin A-1, has been recently shown to have a better efficacy in experimental models than the clinically active, close structural analogue, combretastatin A-4 phosphate (CA4P).
  • MATERIALS AND METHODS: In this study the synergistic effects of administering CA1P in combination with cisplatin (CPL) in a well-differentiated transplantable murine colon model (MAC 29) was evaluated.
  • CONCLUSION: These data demonstrate that the combination of CA1P and CPL has significant preclinical antitumour activity against a transplantable murine adenocarcinoma model that is related to the antivascular effects of CA1P.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Angiogenesis Inhibitors / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / pharmacology. Colonic Neoplasms / pathology. Stilbenes / pharmacology
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Drug Screening Assays, Antitumor. Drug Synergism. Female. Mice. Mice, Inbred Strains. Neoplasm Transplantation

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12820431.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA44344-07-12
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Stilbenes; 109971-63-3 / combretastatin A-1; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Handa R, Kato T, Miyake Y, Oshima K, Oshima S, Iijima S, Yamamoto H, Kurokawa E, Kikkawa N: [A long term survival case of advanced colon cancer with adjacent organ involvement and multiple liver metastases]. Gan To Kagaku Ryoho; 2006 Nov;33(12):1795-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A long term survival case of advanced colon cancer with adjacent organ involvement and multiple liver metastases].
  • We report a long-term survival case of advanced colon cancer with adjacent organ involvement and multiple liver metastases.
  • An advanced colon cancer of the cecum was found with a colonoscopy.
  • Histopathologically, it was a moderately differentiated adenocarcinoma with a biopsy examination.
  • Abdominal CT showed advanced colon cancer with adjacent organ involvement and multiple liver metastases.
  • He received right hemi-colon resection and right hepatic lobectomy.
  • The patient was followed by 8 courses of adjuvant chemotherapy with 5-FU.
  • He has been doing well without any recurrence for five years and six months after the operation.
  • [MeSH-major] Adenocarcinoma / secondary. Cecal Neoplasms / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Chemotherapy, Adjuvant. Colectomy. Fluorouracil / therapeutic use. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Survivors

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212110.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Mori T, Hirota T, Ohashi Y, Kodaira S, Prospective Trial of Adjuvant Chemotherapy for Colon Cancer Study Group (PAC): Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer. Dis Colon Rectum; 2006 Jul;49(7):982-92
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer.
  • PURPOSE: This study was designed to investigate whether the histologic types of the primary lesion and of metastatic lymph nodes in Stage III colon cancer are useful as prognostic factors.
  • The usefulness of adjuvant chemotherapy in a randomized, controlled trial by using these prognostic factors as stratification criteria was also investigated.
  • METHODS: Stage III colon cancer patients were enrolled and were divided into two groups: Group W, in which the histologic type of both primary tumors and metastatic lymph nodes was well-differentiated adenocarcinoma; and Group U, in which the primary tumors and the metastatic lymph nodes were of any type other than well-differentiated.
  • Group W patients were assigned to Treatment Arm A (surgery alone) or Arm B (surgery, then 1-hexylcarbamoyl-5-fluorouracil); and Group U patients, to Treatment Arm C (same as B), and Arm D (surgery + 1-hexylcarbamoyl-5-fluorouracil + mitomycin C).
  • There was a better survival rate in Treatment Arm A than Arm B (P = 0.0321), but no difference between Treatment Arms C and D.
  • CONCLUSIONS: In Stage III colon cancer, the prognosis of cases whose primary lesion and lymph node tissues are both well differentiated is extremely good.
  • In such cases, it is possible for adjuvant chemotherapy to have a deleterious effect, and therefore, it is not recommended.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology
  • [MeSH-minor] Alkylating Agents / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Chemotherapy, Adjuvant / methods. Combined Modality Therapy / methods. Disease-Free Survival. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis / pathology. Mitomycin / administration & dosage. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Analysis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625329.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Nozoe Y, Ogata Y, Miyagi Y, Nakagawa M, Matono K, Sasatomi T, Araki Y, Shirouzu K: [Efficacy of postoperative adjuvant chemotherapy for colorectal cancer]. Gan To Kagaku Ryoho; 2002 Jan;29(1):67-72
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of postoperative adjuvant chemotherapy for colorectal cancer].
  • We attempted postoperative adjuvant chemotherapy for stage II or III colorectal cancer.
  • To investigate the efficacy of the adjuvant chemotherapy, we retrospectively reviewed all 293 colorectal cancer patients who underwent curative resection between 1990 and 1996 in Kurume University Hospital.
  • The patients were divided into two groups according to whether or not they received postoperative adjuvant chemotherapy.
  • The disease-free survival rate in Group 1 was significantly higher than that in Group 2, but only for those with rectal cancer, with no significant difference for those with colon cancer.
  • Findings were similar between the two groups for those with stage II, stage IIIa, a low grade of lymphatic and venous invasion, and well-differentiated adenocarcinoma.
  • Postoperative adjuvant chemotherapy in colorectal cancer might reduce the risk of recurrence, particularly in cases of rectal cancer.
  • However, postoperative adjuvant chemotherapy was insufficient for those with highly advanced cancer or a biologically aggressive tumor.
  • [MeSH-major] Colonic Neoplasms / drug therapy. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Chemotherapy, Adjuvant. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Postoperative Care. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11816480.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Fleckenstein GH, Gunawan B, Brinck U, Wuttke W, Emons G: Simultaneous sertoli cell tumor and adenocarcinoma of the tunica vaginalis testis in a patient with testicular feminization. Gynecol Oncol; 2002 Mar;84(3):460-3
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous sertoli cell tumor and adenocarcinoma of the tunica vaginalis testis in a patient with testicular feminization.
  • BACKGROUND: The association of testicular feminization with late diagnosis in a patient with a large Sertoli cell tumor and a metastasizing adenocarcinoma of the tunica vaginalis testis is unusual.
  • Histologically, we found a well-differentiated Sertoli cell tumor and an adenocarcinoma of the tunica vaginalis testis with metastases in the sigmoid colon, rectum, and omentum.
  • After debulking surgery to optimal residual disease and four courses of chemotherapy (cisplatin and etoposide), there was no evidence of disease (clinically) for 24 months before an intraabdominal and inguinal relapse occurred.
  • Due to the unwillingness of the patient to receive salvage chemotherapy or palliative abdominal surgery, the disease progressed rapidly and she died 27 months after the initial operation.
  • Surgical debulking and platinum-based chemotherapy rendered the patient clinically free of disease for 2 years.
  • [MeSH-major] Adenocarcinoma / pathology. Androgen-Insensitivity Syndrome / pathology. Sertoli Cell Tumor / pathology. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Testicular Feminization.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11855889.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Shnyder SD, Cooper PA, Gyselinck N, Hill BT, Double JA, Bibby MC: Vinflunine potentiates the activity of cisplatin but not 5-fluorouracil in a transplantable murine adenocarcinoma model. Anticancer Res; 2003 Nov-Dec;23(6C):4815-20
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vinflunine potentiates the activity of cisplatin but not 5-fluorouracil in a transplantable murine adenocarcinoma model.
  • BACKGROUND: Vinflunine is a novel Vinca alkaloid currently undergoing Phase II clinical trials, which have previously demonstrated anti-vascular effects in a transplantable murine colon adenocarcinoma model.
  • MATERIALS AND METHODS: In this study the synergistic effects of administering vinflunine in combination with either Cisplatin (CPL) or 5-fluorouracil (5-FU) were investigated in a well-differentiated transplantable murine colon adenocarcinoma model (MAC 29).
  • Using Hoescht 33342 dye labelling of the functional vasculature, clear evidence of vascular shutdown was seen for treatment groups including vinflunine.
  • CONCLUSION: These data demonstrate that the combination of vinflunine and CPL has significant preclinical anti-tumour activity against a transplantable murine adenocarcinoma model that is related to the anti-vascular effects of vinflunine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Fluorouracil / therapeutic use. Vinblastine / analogs & derivatives. Vinblastine / therapeutic use
  • [MeSH-minor] Animals. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Disease Models, Animal. Female. Mice. Mice, Inbred Strains. Neoplasm Transplantation. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14981930.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 5BF646324K / vinflunine; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


21. Mercier I, Vuolo M, Jasmin JF, Medina CM, Williams M, Mariadason JM, Qian H, Xue X, Pestell RG, Lisanti MP, Kitsis RN: ARC (apoptosis repressor with caspase recruitment domain) is a novel marker of human colon cancer. Cell Cycle; 2008 Jun 1;7(11):1640-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ARC (apoptosis repressor with caspase recruitment domain) is a novel marker of human colon cancer.
  • The ability of cells to escape apoptosis is critical for carcinogenesis as well as resistance to radiation and chemotherapy.
  • ARC is expressed predominantly in terminally differentiated cells such as cardiac and skeletal myocytes and neurons.
  • Recently, however, the abundance of ARC was noted to be markedly increased in the epithelium of primary human breast cancers compared with benign breast tissue and to confer chemo- and radiation-resistance.
  • In this study, we assessed the abundance and subcellular localization of ARC in 21 human colon cancer cell lines and in 44 primary human colon adenocarcinomas and adjacent benign colonic tissue.
  • ARC was present at high levels in most colon cancer cell lines and in almost all primary colon cancers compared with corresponding controls.
  • Levels of ARC in the cytoplasm were increased in well, moderately, and poorly differentiated cancers compared with benign tissue, while levels of nuclear ARC were increased only in moderately differentiated tumors.
  • These results demonstrate that ARC is a novel marker of human colon cancer and suggest that it may be a general feature of epithelial cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptosis Regulatory Proteins / genetics. Biomarkers, Tumor / genetics. Colonic Neoplasms / metabolism. Muscle Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469522.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA-098779; United States / NCI NIH HHS / CA / R01-CA-120876; United States / NCI NIH HHS / CA / R01-CA-80250; United States / NHLBI NIH HHS / HL / R01HL60665; United States / NHLBI NIH HHS / HL / R01HL61550; United States / NHLBI NIH HHS / HL / R01HL80607
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / Muscle Proteins; 0 / NOL3 protein, human
  •  go-up   go-down


22. Hsu TC: Unusual elevation of CEA in a patient with history of colon cancer. Jpn J Clin Oncol; 2006 Dec;36(12):811-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual elevation of CEA in a patient with history of colon cancer.
  • A 35-year-old female received right hemicolectomy for a poorly differentiated adenocarcinoma of the ascending colon with lymph node metastasis (1/28) in February 1997.
  • Adjuvant chemotherapy with weekly 5-FU and leucovorin intravenously was started following surgery and discontinued after 17 doses in May 1997.
  • Intravenous chemotherapy was resumed with weekly 5-FU and leucovorin intravenously in August 1999.
  • Intravenous chemotherapy was discontinued after 20 doses and oral chemotherapy with futraful and leucovorin was started in January 2000.
  • The CEA for the patient ranged from 68.5 to 298.9 ng/microl for the following 5 years without aggressive chemotherapy.
  • The current case suggested that: (i) elevation of CEA is not necessarily well correlated with presence of metastatic colon cancer;.
  • (iii) aggressive chemotherapy may not be necessary in patients with only elevated CEA.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoembryonic Antigen / blood. Colonic Neoplasms / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17060406.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


23. Nishigori T, Matsumoto H, Nakano D, Yamaguchi T, Takahashi K, Iwasaki Y, Ohashi M, Nunobe S, Iwanaga T, Nemoto T, Funada N, Nakaya H, Ookura Y: [A case of submucosal invasive cancer of the sigmoid colon, recurring as multiple liver metastases one year after the surgery]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2144-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of submucosal invasive cancer of the sigmoid colon, recurring as multiple liver metastases one year after the surgery].
  • A 55-year-old woman underwent colonoscopy due to a positive fecal occult blood test during a mass screening examination, and a 0-Ip type early cancer in the sigmoid colon was found.
  • Histological examination of the endoscopic resected specimen showed a well-differentiated adenocarcinoma invading submucosal layer (depth of invasion, 6,000 microm), positive lymph vessel invasion, and cut end negative.
  • After the surgery, 8 courses of oral UFT/LV therapy as adjuvant chemotherapy were administered.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Colonoscopy. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Recurrence. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106551.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


24. Shiba Y, Umekita N, Noda K, Kitamura M: [A case report of recurrence of liver metastases from colorectal cancer, which seemed to have vanished for a time by intra-aortic chemotherapy]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1829-31
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of recurrence of liver metastases from colorectal cancer, which seemed to have vanished for a time by intra-aortic chemotherapy].
  • The diagnosis was Stage IV well-differentiated tubular adeno carcinoma. n1H3M(-).
  • As adjuvant chemotherapy, we chose intra-arterial infusion of 5-FU 1,500 mg/body/week from July 2002 to February 2003.
  • As the strategy for liver metastasis of colon cancer, it is better to perform a surgical resection as soon as the focus becomes resectable.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antimetabolites, Antineoplastic / administration & dosage. Colorectal Neoplasms / pathology. Fluorouracil / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Combined Modality Therapy. Hepatectomy. Humans. Infusions, Intra-Arterial. Male. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315954.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


25. Yaacob NS, Darus HM, Norazmi MN: Modulation of cell growth and PPARgamma expression in human colorectal cancer cell lines by ciglitazone. Exp Toxicol Pathol; 2008 Sep;60(6):505-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lactate dehydrogenase release assay showed that ciglitazone potently inhibited HT-29 (well-differentiated) and COLO-205 (poorly differentiated) colorectal adenocarcinoma cell growth.
  • Measurement of apoptosis by flow cytometry using a fluorescein-conjugated monoclonal antibody against cytokeratin 18 revealed a high induction of apoptosis by ciglitazone in a time-dependent fashion.
  • The expression of PPARgamma1 but not PPARgamma2 mRNA was significantly downregulated as measured by real-time quantitative PCR, and the PPARgamma protein levels were decreased as determined by Western blot analysis.
  • We conclude that ciglitazone treatment suppressed colon cancer cell growth via induction of apoptosis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Colorectal Neoplasms / drug therapy. Gene Expression Regulation, Neoplastic / drug effects. Hypoglycemic Agents / pharmacology. PPAR gamma / genetics. Thiazolidinediones / pharmacology
  • [MeSH-minor] Apoptosis / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Down-Regulation. Drug Screening Assays, Antitumor. Humans. L-Lactate Dehydrogenase / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18579355.001).
  • [ISSN] 0940-2993
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Hypoglycemic Agents; 0 / PPAR gamma; 0 / Thiazolidinediones; 74772-77-3 / ciglitazone; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


26. Blair S, Ellenhorn JD: Transanal excision for low rectal cancers is curative in early-stage disease with favorable histology. Am Surg; 2000 Sep;66(9):817-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Controversy still exists as to the optimal treatment of early-stage low rectal cancers.
  • All T1 lesions were well or moderately well differentiated, and none had lymphovascular invasion.
  • Four patients had postoperative adjuvant therapy (radiation alone, two; radiation and chemotherapy, two) for close margins after they refused an abdominal perineal resection.
  • This series suggests that transanal excision is a safe and effective treatment for selected early low rectal cancers with favorable histology.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Aged. Anastomosis, Surgical. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Chemotherapy, Adjuvant. Colon / surgery. Colostomy. Databases as Topic. Female. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Perineum / surgery. Postoperative Complications / surgery. Prospective Studies. Radiotherapy, Adjuvant. Registries. Safety. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10993607.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


27. Heinrich S, Clavien PA: Ampullary cancer. Curr Opin Gastroenterol; 2010 May;26(3):280-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: This manuscript reviews the recent literature on ampullary cancer, including new staging definitions, histological characteristics and treatment options.
  • These histological subtypes can be differentiated by immunohistochemistry: while positivity for mucin-2 (MUC2) and caudal homeobox gene transcription factor-2 (CDX2) excludes the pancreatobiliary subtype, positivity for MUC1 and cytokeratin-17 (CK17) excludes the intestinal subtype.
  • Also, different mechanisms of cancer development have been described, which might be related to the type of differentiation.
  • Due to the very low risk of lymphatic spread, local resections appear sufficient for well differentiated T1 cancer smaller than 1 cm, whereas larger, less differentiated or more invasive cancer requires a radical resection.
  • As cancer with intestinal differentiation shares a similar biology with colon cancer, and the pancreatobiliary differentiation is close to ductal adenocarcinoma of the pancreas, adjuvant chemotherapy should probably be given according to colon cancer (intestinal) and pancreatic cancer (pancreatobiliary), respectively.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20168227.001).
  • [ISSN] 1531-7056
  • [Journal-full-title] Current opinion in gastroenterology
  • [ISO-abbreviation] Curr. Opin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


28. Seront E, Marot L, Coche E, Gala JL, Sempoux C, Humblet Y: Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab. Cancer Treat Rev; 2010 Feb;36 Suppl 1:S11-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Recent approval and introduction into clinical practice of epidermal growth factor receptor inhibitors such as the chimeric monoclonal antibody cetuximab and the fully human monoclonal antibody panitumumab have provided new treatment options for chemotherapy-refractory patients.
  • Here, we report a case of a 47-year-old man with metastatic, chemotherapy-refractory colorectal cancer who achieved long-term partial remission during panitumumab therapy.
  • A computed tomography (CT) scan revealed a voluminous and perforated abscess with a suspected tumour lesion in the sigmoid colon.
  • The patient underwent sigmoidectomy and was diagnosed with a poorly differentiated necrotic carcinoma of the sigmoid colon with invasion in 13 of 19 tested lymph nodes.
  • A colonoscopy revealed multiple tubular adenomas and a positron emission tomography CT scan showed multiple and bilateral hyperfixating lumbar-aortic lymph nodes leading to a final tumour classification of T4N2M1.
  • The patient achieved a partial response following six cycles of FOLFIRI (irinotecan, 5-fluorouracil, leucovorin), then progressed and was enrolled in a trial where he received treatment with FOLFOX4 (oxaliplatin, leucovorin and 5-fluorouracil) with or without a vascular endothelial growth factor inhibitor (PTK787/ZK 222584 [valatinib]).
  • A partial response was noted after 8 weeks of therapy along with a rapid CEA reduction and decrease in lymph node size.
  • The patient is continuing panitumumab treatment and is still in partial remission after 65 months' treatment.
  • During treatment the patient has on occasion experienced grade 1-2 diarrhoea as well as folliculitis and acne-like rash up to grade 3 in severity.
  • CONCLUSION: This case shows that long-term responses are possible during panitumumab therapy and that this agent may be an effective long-term treatment option for selected patients with metastatic colorectal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Colorectal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Clinical Trials as Topic. Diarrhea / chemically induced. Exanthema / chemically induced. Fluorouracil / therapeutic use. Folliculitis / chemically induced. Humans. Leucovorin / therapeutic use. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Treat Rev. 2010 Feb;36 Suppl 1:S15-6 [20189055.001]
  • (PMID = 20189054.001).
  • [ISSN] 1532-1967
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / panitumumab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


29. Krieg RC, Messmann H, Schlottmann K, Endlicher E, Seeger S, Schölmerich J, Knuechel R: Intracellular localization is a cofactor for the phototoxicity of protoporphyrin IX in the gastrointestinal tract: in vitro study. Photochem Photobiol; 2003 Oct;78(4):393-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Photodynamic therapy (PDT) is a new treatment modality for solid tumors as well as for flat lesions of the gastrointestinal tract.
  • Three human colon carcinoma cell lines with variable degrees of differentiation and a normal colon fibroblast cell line were used to generate a suitable in vitro model for investigation of photosensitizer concentration as well as the applied light dose.
  • Well-differentiated tumor cells showed higher toxicity than less-differentiated cells.
  • [MeSH-major] Digestive System / drug effects. Photosensitizing Agents / adverse effects. Protoporphyrins / adverse effects
  • [MeSH-minor] Adenocarcinoma / drug therapy. Colonic Neoplasms / drug therapy. Humans. Photochemotherapy / adverse effects. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14626668.001).
  • [ISSN] 0031-8655
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX
  •  go-up   go-down


30. Popovich IG, Zabezhinski MA, Egormin PA, Tyndyk ML, Anikin IV, Spasov AA, Semenchenko AV, Yashin AI, Anisimov VN: Insulin in aging and cancer: antidiabetic drug Diabenol as geroprotector and anticarcinogen. Int J Biochem Cell Biol; 2005 May;37(5):1117-29
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin in aging and cancer: antidiabetic drug Diabenol as geroprotector and anticarcinogen.
  • The effects of new antidiabetic drug Diabenol (9-beta-diethylaminoethyl-2,3-dihydroimidazo-(1,2-alpha)benzimidazol dihydrochloride) on life span and spontaneous tumor incidence in NMRI and transgenic HER-2/neu mice as well as on colon carcinogenesis induced by 1,2-dimethylhydrazine in rats are studied.
  • It is shown that treatment with the drug failed influence body weight gain dynamics, food and water consumption and the body temperature, slowed down age-related disturbances in estrous function and increased life span of all and 10% most long-living NMRI mice.
  • The treatment with Diabenol inhibited spontaneous tumor incidence and increased the mammary tumor latency in these mice.
  • Diabenol treatment slowed down age-related changes in estrous function in HER-2/neu mice, failed influence survival of these mice and slightly inhibited the incidence and decreased the size of mammary adenocarcinoma metastases into the lung.
  • In rats exposed to 1,2-dimethylhydrazine, treatment with Diabenol significantly inhibited multiplicity of all colon tumors, decreased by 2.2 times the incidence of carcinomas in ascending colon and by 3.1 times their multiplicity.
  • Treatment with Diabenol was followed by higher incidence of exophytic and well-differentiated colon tumors as compared with the control rats exposed to the carcinogen alone (76.3% and 50%, and 47.4% and 14.7%, respectively).
  • Thus, the drug increases survival and inhibits spontaneous carcinogenesis in mice and inhibits colon carcinogenesis in rats.
  • [MeSH-major] Aging. Anticarcinogenic Agents / therapeutic use. Benzimidazoles / therapeutic use. Hypoglycemic Agents / therapeutic use
  • [MeSH-minor] 1,2-Dimethylhydrazine / pharmacology. Age Factors. Animals. Body Temperature. Body Weight. Colonic Neoplasms / drug therapy. Feeding Behavior. Female. Insulin / physiology. Mammary Neoplasms, Experimental / drug therapy. Mice. Mice, Inbred Strains. Mice, Transgenic. Neoplasms / drug therapy. Rats

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. 1,2-DIMETHYLHYDRAZINE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15743682.001).
  • [ISSN] 1357-2725
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 9-diethylaminoethyl-2,3-dihydroimidazo(1,2alpha)benzimidazole; 0 / Anticarcinogenic Agents; 0 / Benzimidazoles; 0 / Hypoglycemic Agents; 0 / Insulin; IX068S9745 / 1,2-Dimethylhydrazine
  •  go-up   go-down


31. Takahashi Y: [Gastrointestinal cancer]. Gan To Kagaku Ryoho; 2004 Aug;31(8):1275-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The sensitivity of CEA, CA 19-9, is relatively high, especially in well-differentiated adenocarcinoma of gastric cancer with lymph node metastasis.
  • CEA, CA 19-9, is useful for colon cancer, especially for predicting preoperative staging.
  • Half-life and doubling time of tumor markers is useful in some cases for the evaluation of operation and chemotherapy.
  • Recurrent diseases were detected between 5 months after detection by diagnostic imagings and 12 months before detection by diagnostic imagings (mean of 3.1+/-3.6 months before detection by diagnostic imagings) and between 10 months after detection by diagnostic imagings and 13 months before detection by diagnostic imagings (mean 2.2+/-3.9 months before detection by diagnostic imagings) by CEA and CA 19-9 monitorings, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15332558.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen
  • [Number-of-references] 18
  •  go-up   go-down


32. Phillips TE, McHugh J, Moore CP: Cyclosporine has a direct effect on the differentiation of a mucin-secreting cell line. J Cell Physiol; 2000 Sep;184(3):400-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cyclosporine is a potent immunosuppressant used in the treatment of ulcerative colitis and keratoconjunctivitis sicca.
  • Neither the etiologies of these diseases nor the mechanism by which cyclosporine exerts its therapeutic effect is well understood.
  • The HT29-18N2 human colon adenocarcinoma cell line, which is capable of forming monolayers of well-differentiated goblet cells, was used as a model system.
  • The intracellular accumulation of mucin was not a result of reduced secretion, since the time required for the release of pulse-radiolabeled glycoproteins was similar for both control and cyclosporine-treated monolayers.
  • The effect of cyclosporine was not mediated by the drug's previously documented abilities to decrease cellular proliferation rates, inhibit calmodulin, antagonize prolactin receptor binding, or modulate prostaglandin production.
  • [MeSH-major] Cyclosporine / pharmacology. Goblet Cells / cytology. Goblet Cells / drug effects. Mucins / secretion
  • [MeSH-minor] Calmodulin / antagonists & inhibitors. Cell Differentiation / drug effects. Cell Division / drug effects. Cell Line. Colitis, Ulcerative / drug therapy. Cyclosporins / pharmacology. Glycoproteins / secretion. Humans. Immunosuppressive Agents / pharmacology. Keratoconjunctivitis Sicca / drug therapy. Prolactin / antagonists & inhibitors. Prostaglandin-Endoperoxide Synthases / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10911372.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / EY10594
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Calmodulin; 0 / Cyclosporins; 0 / Glycoproteins; 0 / Immunosuppressive Agents; 0 / Mucins; 121584-18-7 / valspodar; 83HN0GTJ6D / Cyclosporine; 9002-62-4 / Prolactin; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down






Advertisement